HKHelena Krysztofiak

Helena Krysztofiak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Helena Krysztofiak has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Iron deficiency and nutritional status in heart failure with reduced ejection fraction: a cross-sectional study

    by Marta Kałużna-Oleksy, Filip Sawczak, Aleksandra Soloch, Maria Cierzniak, Alicja Szubarga, Agata Kukfisz, Helena Krysztofiak, Magdalena Dudek, Michał Hawranek, Ewa Straburzyńska-Migaj

    Iron deficiency (ID) impacts prognosis and quality of life for heart failure (HF) patients. It is essential to actively search for ID in this group and establish its relationship with nutritional status. The aim was to determine the relationship between nutritional status according to the Mini Nutritional Assessment (MNA) questionnaire and the presence of ID in heart failure patients with reduced ejection fraction (HFrEF). The study sample comprized 272 HFrEF patients. Collected on admission were: medical history, echocardiographic and biochemical parameters. Iron deficiency was diagnosed if ferritin was < 100 ng/mL or < 300 ng/mL with transferrin saturation (TSAT) < 20%. Nutritional status was assessed using the MNA form and body mass index (BMI). The cohort was 81.6% male and 18.4% female. The median age was 59 (IQR 50-64) years, and the mean BMI was 28.8 ± 5.3 kg/m². 54.4% of patients showed New York Heart Association (NYHA) class III or IV HF symptoms. Iron deficiency was detected in 55.5% of patients. Participants at risk of malnutrition constituted 45.2%, while 1.8% were malnourished. In the ID group 45% were at risk of malnutrition and 2.6% were malnourished, compared with 45.4% (p = 1.00) and 0.8% (p = 0.39) in the no-ID group. Female sex and atrial fibrillation(AF) were associated with ID. Nutritional status assessed by the MNA questionnaire is not related to the presence of ID in HFrEF. Female sex and AF are risk factors for ID in this group.


  • Open Access

    Neutrophil-lymphocyte ratio (NLR) as an independent factor of 1-year mortality in patients with chronic heart failure with reduced ejection fraction

    by Filip Sawczak, Helena Krysztofiak, Agata Kukfisz, Martyna Piszczek, Magdalena Szczechla, Katarzyna Przytarska, Magdalena Dudek, Izabella Uchmanowicz, Małgorzata Tomaszewska, Ewa Straburzyńska-Migaj, et al.

    Background: Inflammatory components play a prominent role in the pathogenesis of heart failure (HF) and correlate with the progression and severity of the disease. The aim of the present study was to assess the association between the neutrophil-lymphocyte ratio (NLR) and mortality risk in patients with stable HF with reduced ejection fraction (HFrEF). Methods: A total of 140 patients hospitalized due to a scheduled routine examination without HF exacerbations were included. NLR was calculated as follows: NLR = neutrophil level [G/L]/lymphocyte level [G/L]. Results: The average age in the study sample was 54.1 ± 11.3 years. NLR was significantly associated with co-existing atrial fibrillation and parameters related to nutrition: total cholesterol, triglycerides, low-density lipoproteins, and albumin. During a median follow-up (365 days; IQR 296.5–365), 17 (12.1%) patients died. The log-rank test showed the worst survival rate in the highest NLR tertile. A higher NLR value was an independent predictor of 1-year mortality (HR 1.326, 95% CI: 1.121–1.569, p = 0.0010) after adjustment for natriuretic peptides, comorbidities, and other clinical parameters. It retained its value even after the exclusion of patients with severe kidney dysfunction (eGFR < 30mL/min/1.73m2) and with chronic obstructive pulmonary disease (COPD). Conclusions: Neutrophil-lymphocyte ratio could be deployed as an auxiliary, no-cost marker of worse 1-year prognosis in stable HFrEF patients. Keywords: Complete blood count lymphocyte count nutrition inflammation mortality determinants neutrophil-lymphocyte ratio


  • Open Access

    Correlations between soluble ST2 concentration and the nutritional status in patients with heart failure with reduced ejection fraction — cross-sectional study

    by Marta Kałużna-Oleksy, Filip Waśniewski, Magdalena Szczechla, Filip Sawczak, Agata Kukfisz, Helena Krysztofiak, Katarzyna Przytarska, Ewa Straburzyńska-Migaj, Magdalena Dudek

    Background: Heart failure (HF) is a global problem that stimulates research on markers associated with the diagnosis and course of the disease. Soluble suppression of tumorigenicity-2 (sST2) is a receptor for interleukin-33 and is associated with increased mortality rates in HF patients. Malnutrition in HF is also connected with inflammation and is associated with worse prognosis. The present study aimed to evaluate the relationship between sST2 concentration and the nutritional status of patients with HF with reduced ejection fraction (HFrEF). Material and methods: 138 patients with HFrEF were enrolled in this cross-sectional study. Nutritional status was assessed using Geriatric Nutritional Risk Index (GNRI) and Controlling Nutritional Status (CONUT). The mean age was 53.6 ± 10.8 years. Results: In the group with sST2 > 32.9 ng/mL, the GNRI score was higher and the associated risk of malnutrition was more common (29% vs. 12%; p = 0.011). Coherently in the group with sST2 > 32.9 ng/mL the median CONUT score was worse (2 [IQR 1–3] vs. 1 [IQR 0–2]; p = 0.0016) and the risk of malnutrition defined by this tool was also more prevalent (p = 0.0079). This relationship was independent of the concentration of natriuretic peptides, age and sex. Conclusions: According to available research, this research is the first study showing that sST2 concentration is related with nutritional status in HFrEF patients. sST2 may help to evaluate the necessity for nutritional intervention in HFrEF patients. Keywords: biomarkers heart failure HFrEF nutritional status suppression of tumorigenicity-2 ST2 malnutrition


  • Intravascular Ultrasound for the Prevention of Coronary Artery Occlusion During Transcatheter Aortic Valve Replacement

    by Helena Krysztofiak, Krzysztof Krawczyk, Witold Gwóźdź, Jerzy Sacha

    Predicting coronary artery occlusion after transcatheter aortic valve replacement (TAVR) is usually based on computed tomography angiography (CTA). The primary risk factors seem to be a low coronary artery take‐off and a small aortic root. However, CTA sometimes provides ambiguous risk assessment, and even if a potentially risky coronary artery is secured with a guidewire, the need for coronary stenting after valve implantation often remains uncertain. To reduce uncertainty, intravascular ultrasound (IVUS) can be used. The following two cases highlight the utility of IVUS in addressing these issues.

  • Sex differences in the nutritional status and its association with long-term prognosis in patients with heart failure with reduced ejection fraction: a prospective cohort study

    by Marta Kałużna-Oleksy, Helena Krysztofiak, Filip Sawczak, Agata Kukfisz, Magdalena Szczechla, Aleksandra Soloch, Maria Cierzniak, Alicja Szubarga, Katarzyna Przytarska, Magdalena Dudek, et al.

    Many studies show the association between malnutrition and poor prognosis in heart failure (HF) patients. Our research aimed to analyse sex differences in patients with HF with reduced ejection fraction (HFrEF), emphasizing nutritional status and the influence of selected parameters on the prognosis. We enrolled 276 consecutive patients diagnosed with HFrEF. Nutritional status was assessed using Mini Nutritional Assessment (MNA), geriatric nutritional risk index (GNRI), and body mass index (BMI). The mean follow-up period was 564.4 ± 346.3 days. The analysed group included 81.2% of men. The median age was 58, interquartile range (IQR) 49–64 years. Among all patients, almost 60% were classified as NYHA III or IV. Half of the participants were at risk of malnutrition, and 2.9% were malnourished. During follow-up, 72 (26.1%) patients died. The female sex was not associated with a higher occurrence of malnutrition (P = 0.99) or nutritional risk (P = 0.85), according to MNA. Coherently, GNRI scores did not differ significantly between the sexes (P = 0.29). In contrast, BMI was significantly higher in males (29.4 ± 5.3 vs. 25.9 ± 4.7; P < 0.001). Impaired nutritional status assessed with any method (MNA, GNRI, BMI) was not significantly associated with a worse prognosis. In multivariable analysis, NYHA class, lower estimated glomerular filtration rate, higher B-type natriuretic peptide (BNP), higher N-terminal fragment of proBNP, and higher uric acid were independent of sex and age predictors of all-cause mortality. There were no sex differences in the nutritional status in the HFrEF patients, apart from lower BMI in females. Impaired nutritional status was not associated with mortality in both men and women.


  • Open Access

    Relationship of pre-pandemic quality of life and avoiding vaccination against SARS-CoV-2 in patients with heart failure – a cohort study

    by Filip Sawczak, Agata Kukfisz, Maria Cierzniak, Alicja Szubarga, Aleksandra Soloch, Anita Balewska, Magdalena Szczechla, Helena Krysztofiak, Katarzyna Przytarska, Magdalena Dudek, et al.

    Heart failure (HF) patients are vulnerable to a complicated course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The aim of this research was to analyze the relationship between the decision not to be immunized against SARS-CoV-2, clinical, epidemiological factors and pre-pandemic health-related quality of life (HRQoL) of HF patients . Prior to the onset of the SARS-CoV-2 pandemic, hospitalized HF patients were enrolled as a prospective cohort and interviewed with World Health Organization Quality of Life Brief Version questionnaire. On October 30, 2021, the immunization status was verified. The association of vaccination hesitancy with epidemiological and clinical parameters, and pre-pandemic questionnaire results was tested. Subsequently, the independence from confounding factors, age, sex, New York Heart Association (NYHA) scale, and left ventricular ejection fraction (LVEF) was analyzed. Among 136 included patients, 77.9% were vaccinated. Unvaccinated patients were younger (51.2±13.2 vs 56.6±10.3; p=0.018) and more frequently had non-ischemic etiology of HF (73.3% vs. 46.7%; p=0.013). It was significant after adjustment for age, sex, NYHA class and LVEF. There was no association of overall HRQoL or domain scores with vaccination status. Younger age as a factor associated with vaccine avoidance in this population is consistent with data from the general population despite higher exposure to the severe course of the disease.

  • Open Access

    Cardiac Cachexia: A Well-Known but Challenging Complication of Heart Failure

    by Helena Krysztofiak, Marta Wleklik, Jacek Migaj, Magdalena Dudek, Izabella Uchmanowicz, Magdalena Lisiak, Grzegorz Kubielas, Ewa Straburzyńska-Migaj, Maciej Lesiak, Marta Kałużna-Oleksy

    Heart failure (HF) is a common complication of various cardiac diseases, and its incidence constantly increases. This is caused mainly by aging of populations and improvement in the treatment of coronary artery disease. As HF patients age, they tend to develop comorbidities, creating new problems for health-care professionals. Sarcopenia, defined as the loss of muscle mass and function, and cachexia, defined as weight loss due to an underlying illness, are muscle wasting disorders of particular relevance in the heart failure population, but they go mostly unrecognized. The coexistence of chronic HF and metabolic disorders facilitates the development of cachexia. Cachexia, in turn, significantly worsens a patient’s prognosis and quality of life. The mechanisms underlying cachexia have not been explained yet and require further research. Understanding its background is crucial in the development of treatment strategies to prevent and treat tissue wasting. There are currently no specific European guidelines or recommended therapy for cachexia treatment in HF (“cardiac cachexia”).